Diligence memo · auto-generated · as of July 2, 2026
TearSolutions, Inc.
TearSolutions, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
TearSolutions, Inc. operates in Biotechnology, based in Charlottesville.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
TearSolutions, Inc. has raised $40M in disclosed capital across 11 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $13M on 2024-09-25.
Most recent recorded round closed around 2025-10-29.
Valuation (modeled)modeled
Provath models TearSolutions, Inc. at approximately $1.4M (range $564K–$2.3M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.09× the median modeled value of Series A Biotechnology companies in 2025–2027 (156 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 8 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 24.6× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 78% of Biotechnology peers (4291 compared).
Modeled value ranks above 4% of those peers.
Closest niche peers: Acasti Pharma Inc., Edesa Biotech, Inc., 4DMedical Ltd, Arialys Therapeutics, Inc., Nuclein, LLC.
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.